Pylum Biosicences offers an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. The Avidocin platform can be quickly modified to generate new protein complexes to kill emerging strains as their genome sequences become available. Avidocin proteins employ a unique killing mechanismthat is oblivious to the mechanisms bacteria have evolved to resist traditional antibiotics, and because of their tailorable specificity, they can be directed against specific species or strains with minimal or no off-target effects.The company currently has in development Avidocin agents targeting 10 different organisms including threatening human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumonia. Pre-clinical animal studies have demonstrated that Avidocin proteins can be orally or parentally administered to prevent or treat disease with impressive efficacy in multiple infection models.

Biotechnology

Health Care

Pylum Biosciences

Pylum Biosciences' headquarters in San Francisco, CA, United States

David W. Martin

James L. Knighton

Kevin Cameron

Jeffery F. Miller

Rene Russo

Miguel Barbosa

Martin J. Blaser

John J. Mekalanos

Pylum Biosciences

Org chart

Board & advisors

Teams

Offices

Similar companies